$JNJ Johnson & Johnson Q3 Earnings

Adj. EPS $2.59, est. $2.52 Revenue $24.60B, est. $24.21B MedTech Sales $8.64B, est. $8.77B Medicine Revenue $16.76B, est. $16.59B Darzalex Revenue $4.24B, est. $4.31B FY Adj. EPS Outlook $11.05—$11.15, prior $10.96—$11.11 FY Adj. Operating EPS Outlook $10.95—$11.05, prior $10.86—$11.01 FY Sales Outlook $101B—$101.4B, prior $100.8B—$101.4B CFO: Leaning Toward Orthopedic Unit Spinoff Instead of Sale